Valuation: Control Bionics Limited

Market Cap 30.49M 21.34M 18.66M 17.25M 15.83M 29.96M 2.06B 206M 80.83M 1B 80.15M 78.39M 3.47B P/E 2024
-1.4x
P/E 2025 -1.3x
Enterprise Value 30.25M 21.18M 18.51M 17.12M 15.71M 29.73M 2.04B 204M 80.2M 997M 79.53M 77.78M 3.44B EV / Sales 2024
1.92x
EV / Sales 2025 1.4x
Free-Float
54.68%
Yield 2024 *
-
Yield 2025 -
1 day-1.43%
1 week-5.48%
Current month-6.76%
1 month-25.81%
3 months+9.52%
6 months-1.43%
Current year+13.11%
1 week 0.06
Extreme 0.065
0.08
1 month 0.06
Extreme 0.065
0.09
Current year 0.05
Extreme 0.05
0.1
1 year 0.03
Extreme 0.032
0.1
3 years 0.03
Extreme 0.026
0.1
5 years 0.03
Extreme 0.026
0.74
10 years 0.03
Extreme 0.026
1.24
Manager TitleAgeSince
Chief Executive Officer - 19/01/2023
Director of Finance/CFO - 13/05/2024
Chief Tech/Sci/R&D Officer - 01/01/2014
Director TitleAgeSince
Chairman 66 19/11/2025
Director/Board Member - 19/01/2023
Director/Board Member - 01/04/2023
Change 5-day change 1-year change 3-year change Capi.($)
-1.43%-5.48%+60.47%-18.82% 20.19M
+0.75%+3.10%+18.53%-18.91% 17.53B
-3.55%+3.05%+7.19%+95.22% 1.67B
+0.05%+4.59%-33.84%-78.65% 1.24B
-1.87%-6.41%-38.08%+11.69% 1.01B
+1.98%+10.32%-24.47%-50.67% 672M
+2.44%+7.74%-36.04%-54.14% 576M
-0.28%-0.09%+37.95%-53.24% 453M
-1.02%+1.12%-53.94%-58.60% 387M
-3.29%+16.11%+47.89% - 332M
Average -0.62%+2.53%-1.44%-25.12% 2.39B
Weighted average by Cap. +0.29%+4.65%+9.72%-15.73%

Financials

2024 2025
Net sales 5.35M 3.75M 3.27M 3.03M 2.78M 5.26M 361M 36.12M 14.19M 176M 14.07M 13.76M 609M 6.14M 4.3M 3.76M 3.48M 3.19M 6.04M 415M 41.48M 16.29M 202M 16.16M 15.8M 699M
Net income -5.91M -4.14M -3.62M -3.35M -3.07M -5.81M -399M -39.92M -15.68M -195M -15.55M -15.21M -673M -6.11M -4.28M -3.74M -3.46M -3.17M -6M -412M -41.23M -16.2M -201M -16.06M -15.71M -695M
Net Debt -96.95K -67.88K -59.33K -54.87K -50.35K -95.29K -6.54M -654K -257K -3.19M -255K -249K -11.03M -237K -166K -145K -134K -123K -233K -16.01M -1.6M -629K -7.82M -624K -610K -26.99M
Logo Control Bionics Limited
Control Bionics Limited is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses, such as Motor Neurone Disease and Amyotrophic Lateral Sclerosis. Its products include Control Bionics Trilogy Systems, NeuroStrip, NeuroNode, Cosmos Connect and accessories. NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as electromyography output. This output is then sent wirelessly via NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse and the NeuroNode acts like a mouse button. It is commercializing its advancement in its technology, NeuroStrip. It is focused on neuromuscular rehabilitation and athletic optimization.
Employees
-
Date Price Change Volume
17/07/26 $0.0690 -1.43% 1,674,808
16/07/26 $0.0700 -5.41% 2,253,176
15/07/26 $0.0740 -1.33% 530,059
14/07/26 $0.0750 0.00% 1,035,306
13/07/26 $0.0750 +2.74% 230,680

Annual profits - Rate of surprise